#METABOLOMICS WORKBENCH hormel101_20180715_125455_mwtab.txt DATATRACK_ID:1454 STUDY_ID:ST001018 ANALYSIS_ID:AN001666 PROJECT_ID:PR000680 VERSION 1 CREATED_ON July 17, 2018, 2:23 pm #PROJECT PR:PROJECT_TITLE Mayo Pilot and Feasibility: Metabolomics of Muscle Wasting in Cancer Cachexia PR:PROJECT_SUMMARY Cachexia is a debilitating syndrome that results in severe, involuntary weight PR:PROJECT_SUMMARY loss due to the depletion of skeletal muscle mass. This syndrome occurs in a PR:PROJECT_SUMMARY majority of cancers and contributes to approximately one third of all cancer PR:PROJECT_SUMMARY deaths. Currently, no effective therapy exists to combat this malignant PR:PROJECT_SUMMARY disorder, and disappointing results from recent Phase III clinical trials PR:PROJECT_SUMMARY indicate that a cachexia treatment is not likely to appear soon. Thus, it is PR:PROJECT_SUMMARY clear that greater knowledge of the mechanisms driving muscle wasting in PR:PROJECT_SUMMARY cachexia is needed in order to identify new therapeutic targets and stimulate PR:PROJECT_SUMMARY new clinical trials. Our approach to gaining this knowledge has been to work PR:PROJECT_SUMMARY with muscle biopsies from pancreatic cancer patients, since this population is PR:PROJECT_SUMMARY highly prone to cachexia. We have also been expanding our studies beyond the PR:PROJECT_SUMMARY classical mouse models of cancer cachexia in hopes of finding a new model that PR:PROJECT_SUMMARY better recapitulates the human disease. We recently undertook RNA-Seq analysis PR:PROJECT_SUMMARY comparing muscle biopsies from pancreatic cancer patients with and without PR:PROJECT_SUMMARY cachexia, which has been exciting since this type of analysis has not yet been PR:PROJECT_SUMMARY performed in patient samples. Preliminary results revealed that cachectic muscle PR:PROJECT_SUMMARY was associated with alterations in metabolism. These data provide the rationale PR:PROJECT_SUMMARY for performing metabolomics to ascertain whether specific metabolic pathways or PR:PROJECT_SUMMARY metabolites can be identified as potential drivers of muscle wasting in cachexia PR:PROJECT_SUMMARY or be used as biomarker of cachexia, which the field desperately needs. An PR:PROJECT_SUMMARY additional need is a well-validated animal model of cancer cachexia that PR:PROJECT_SUMMARY accurately reflects the human condition, which can be used to test mechanisms PR:PROJECT_SUMMARY and pre-clinical compounds. We propose to perform these studies under the Mayo PR:PROJECT_SUMMARY Clinic Metabolomics Resource Core Pilot and Feasibility Grant program to: 1) PR:PROJECT_SUMMARY Identify metabolic alterations and biomarkers of pancreatic cancer-induced PR:PROJECT_SUMMARY muscle wasting; and 2) Identify a suitable mouse model that recapitulates the PR:PROJECT_SUMMARY metabolic imbalance of muscles from pancreatic cancer cachexia patients. By PR:PROJECT_SUMMARY performing these studies, we will accelerate our understanding of the underlying PR:PROJECT_SUMMARY causes of muscle wasting, which should translate to improving the current PR:PROJECT_SUMMARY pipeline of anticachexia therapies. PR:INSTITUTE Mayo Clinic PR:LAST_NAME Guttridge PR:FIRST_NAME Denis PR:ADDRESS 520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210 PR:EMAIL denis.guttridge@osumc.edu PR:PHONE 614-688-3137 #STUDY ST:STUDY_TITLE Large Scale Profiling in Serum for Muscle Wasting in Cancer Cachexia (part-XII) ST:STUDY_SUMMARY Large Scale Profiling of muscle wasting in Cancer Cachexia. Serum samples from ST:STUDY_SUMMARY 10 control patients, 10 weight stable pancreatic cancer patients, and 10 ST:STUDY_SUMMARY pancreatic cancer patients with significant weight loss. Samples are divided ST:STUDY_SUMMARY evenly between males and females. ST:INSTITUTE Mayo Clinic ST:LAST_NAME Guttridge ST:FIRST_NAME Denis ST:ADDRESS 520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210 ST:EMAIL denis.guttridge@osumc.edu ST:PHONE 614-688-3137 #SUBJECT SU:SUBJECT_TYPE Human SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS 1 nC18-31may17-001 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 2 nC18-31may17-002 Groups:Control | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 3 nC18-31may17-003 Groups:Control | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 4 nC18-31may17-004 Groups:Control | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 5 nC18-31may17-005 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 6 nC18-31may17-006 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 7 nC18-31may17-007 Groups:Control | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 8 nC18-31may17-008 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 9 nC18-31may17-009 Groups:Control | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 10 nC18-31may17-010 Groups:Control | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 11 nC18-31may17-011 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 12 nC18-31may17-012 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 13 nC18-31may17-013 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 14 nC18-31may17-014 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 15 nC18-31may17-015 Groups:Control | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 16 nC18-31may17-016 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 17 nC18-31may17-017 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 18 nC18-31may17-018 Groups:Control | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 19 nC18-31may17-019 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 20 nC18-31may17-020 Groups:Control | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 21 nC18-31may17-021 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 22 nC18-31may17-022 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 23 nC18-31may17-023 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 24 nC18-31may17-024 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 25 nC18-31may17-025 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 26 nC18-31may17-026 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 27 nC18-31may17-027 Groups:Control | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 28 nC18-31may17-028 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 29 nC18-31may17-029 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 30 nC18-31may17-030 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NC18 SUBJECT_SAMPLE_FACTORS 1 pC18-30may17-001 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 2 pC18-30may17-002 Groups:Control | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 3 pC18-30may17-003 Groups:Control | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 4 pC18-30may17-004 Groups:Control | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 5 pC18-30may17-005 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 6 pC18-30may17-006 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 7 pC18-30may17-007 Groups:Control | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 8 pC18-30may17-008 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 9 pC18-30may17-009 Groups:Control | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 10 pC18-30may17-010 Groups:Control | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 11 pC18-30may17-011 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 12 pC18-30may17-012 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 13 pC18-30may17-013 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 14 pC18-30may17-014 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 15 pC18-30may17-015 Groups:Control | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 16 pC18-30may17-016 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 17 pC18-30may17-017 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 18 pC18-30may17-018 Groups:Control | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 19 pC18-30may17-019 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 20 pC18-30may17-020 Groups:Control | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 21 pC18-30may17-021 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 22 pC18-30may17-022 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 23 pC18-30may17-023 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 24 pC18-30may17-024 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 25 pC18-30may17-025 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 26 pC18-30may17-026 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 27 pC18-30may17-027 Groups:Control | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 28 pC18-30may17-028 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 29 pC18-30may17-029 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 30 pC18-30may17-030 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PC18 SUBJECT_SAMPLE_FACTORS 1 nhilic-31may17-001 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 2 nhilic-31may17-002 Groups:Control | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 3 nhilic-31may17-003 Groups:Control | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 4 nhilic-31may17-004 Groups:Control | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 5 nhilic-31may17-005 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 6 nhilic-31may17-006 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 7 nhilic-31may17-007 Groups:Control | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 8 nhilic-31may17-008 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 9 nhilic-31may17-009 Groups:Control | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 10 nhilic-31may17-010 Groups:Control | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 11 nhilic-31may17-011 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 12 nhilic-31may17-012 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 13 nhilic-31may17-013 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 14 nhilic-31may17-014 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 15 nhilic-31may17-015 Groups:Control | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 16 nhilic-31may17-016 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 17 nhilic-31may17-017 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 18 nhilic-31may17-018 Groups:Control | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 19 nhilic-31may17-019 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 20 nhilic-31may17-020 Groups:Control | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 21 nhilic-31may17-021 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 22 nhilic-31may17-022 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 23 nhilic-31may17-023 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 24 nhilic-31may17-024 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 25 nhilic-31may17-025 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 26 nhilic-31may17-026 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 27 nhilic-31may17-027 Groups:Control | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 28 nhilic-31may17-028 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 29 nhilic-31may17-029 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 30 nhilic-31may17-030 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=NHILIC SUBJECT_SAMPLE_FACTORS 1 philic-30may17-001 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 2 philic-30may17-002 Groups:Control | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 3 philic-30may17-003 Groups:Control | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 4 philic-30may17-004 Groups:Control | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 5 philic-30may17-005 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 6 philic-30may17-006 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 7 philic-30may17-007 Groups:Control | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 8 philic-30may17-008 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 9 philic-30may17-009 Groups:Control | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 10 philic-30may17-010 Groups:Control | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 11 philic-30may17-011 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 12 philic-30may17-012 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 13 philic-30may17-013 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 14 philic-30may17-014 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 15 philic-30may17-015 Groups:Control | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 16 philic-30may17-016 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 17 philic-30may17-017 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 18 philic-30may17-018 Groups:Control | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 19 philic-30may17-019 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 20 philic-30may17-020 Groups:Control | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 21 philic-30may17-021 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 22 philic-30may17-022 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 23 philic-30may17-023 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 24 philic-30may17-024 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 25 philic-30may17-025 Groups:Weight Stable | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 26 philic-30may17-026 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 27 philic-30may17-027 Groups:Control | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 28 philic-30may17-028 Groups:Weight Stable | Gender:Male Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 29 philic-30may17-029 Groups:Weight Losing | Gender:Female Sample type=Serum; chromatography=PHILIC SUBJECT_SAMPLE_FACTORS 30 philic-30may17-030 Groups:Weight Losing | Gender:Male Sample type=Serum; chromatography=PHILIC #COLLECTION CO:COLLECTION_SUMMARY Tissue and blood donated from Cancer Cachexia Program at Ohio State University CO:SAMPLE_TYPE Blood (serum) #TREATMENT TR:TREATMENT_SUMMARY "Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, TR:TREATMENT_SUMMARY with the most notable symptom being unintentional weight loss. Cachectic TR:TREATMENT_SUMMARY patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss TR:TREATMENT_SUMMARY and its associated weakness contributing to the morbidity and mortality of these TR:TREATMENT_SUMMARY patients. Despite three decades of research into mechanisms driving muscle TR:TREATMENT_SUMMARY wasting due to cancer, to date, an approved pharmacological therapy to prevent TR:TREATMENT_SUMMARY or treat cancer cachexia is still lacking. Our laboratory focuses on cancer TR:TREATMENT_SUMMARY cachexia in patients with pancreatic cancer, as up to 85% of these patients TR:TREATMENT_SUMMARY experience weight loss. Cachexia often occurs early in the progression of TR:TREATMENT_SUMMARY pancreatic cancer, making clear that cachexia in these patients is not simply a TR:TREATMENT_SUMMARY result of end-stage disease. Further, with perhaps more than ΒΌ of all TR:TREATMENT_SUMMARY pancreatic cancer deaths resulting from muscle weakness as opposed to tumor TR:TREATMENT_SUMMARY burden, cachexia also significantly contributes to mortality due to pancreatic TR:TREATMENT_SUMMARY cancer. Because little progress has been made in improving treatment outcomes, TR:TREATMENT_SUMMARY addressing cancer-induced muscle wasting is perhaps the best strategy to prolong TR:TREATMENT_SUMMARY pancreatic cancer patient survival and increase patient quality of life. In an TR:TREATMENT_SUMMARY effort to better understand the mechanisms driving pancreatic cancer-induced TR:TREATMENT_SUMMARY muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a TR:TREATMENT_SUMMARY Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing TR:TREATMENT_SUMMARY attempted resection for pancreatic cancer or other abdominal surgeries have TR:TREATMENT_SUMMARY donated muscle and blood to our bank. A unique aspect of our tissue bank is our TR:TREATMENT_SUMMARY focus on patients eligible for resection. In contrast to other studies using TR:TREATMENT_SUMMARY patients with late-stage disease, our patients are not end-stage, as they are TR:TREATMENT_SUMMARY considered healthy enough to undergo a major operation. " #SAMPLEPREP SP:SAMPLEPREP_SUMMARY large scale profiling using serum #CHROMATOGRAPHY CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Agilent 1290 Infinity CH:COLUMN_NAME Waters Acquity HSS C18 (150 x 2.1mm, 1.8um) #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:MS_COMMENTS - MS:INSTRUMENT_NAME Agilent 6550 QTOF MS:INSTRUMENT_TYPE QTOF MS:MS_TYPE ESI MS:ION_MODE NEGATIVE MS:MS_RESULTS_FILE ST001018_AN001666_Results.txt UNITS:intensity #END